product summary
Loading...
company name :
HUABIO
product type :
antibody
product name :
Human IL-12B p40
catalog :
HA722629B
quantity :
100μl
price :
409.00 USD
clonality :
monoclonal
host :
domestic rabbit
conjugate :
biotin
clone name :
PSH03-04
reactivity :
human
application :
ELISA
more info or order :
product information
SKU :
HA722629B
Target name :
Human IL-12B p40
Species reactivity :
Human
Applications :
ELISA(Det)
Conjugate :
Biotin-conjugated
Immunogen :
Recombinant protein within human IL-23A aa 20-189.
Uniprot id :
P29460>SwissProt: P29460 Human
Host :
Rabbit
Clone number :
PSH03-04
Isotype :
IgG
Size :
100μl
List Price :
409.00 USD
Storage Buffer :
PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% ProClin300.
Form :
Liquid
Storage Instruction :
Shipped at 4℃. Store at +4℃ short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20℃ long term.
Purity :
Protein A affinity purified.
Product type :
Recombinant Rabbit monoclonal Antibody
Positive control :
Recombinant Human IL-23 protein (HA210909).
Molecular wt :
Predicted band size: 20.7 kDa
Subcellular location :
Secreted.
Concentration :
1 mg/ml
Recommended dilutions :
ELISA(Det): Use at an assay dependent concentration. Can be paired for Sandwich ELISA with Rabbit monoclonal [PSH03-03] to Human Human IL-23 (Detector) (HA721933) and recombinant Human IL-23 protein (HA210909) as the standard. The reference range value is 37-3000 pg/ml.
more info or order :
company information

HUABIO
Founded in 2007, HUABIO is dedicated to developing high-quality antibodies that advance innovation. We are passionate about the accuracy, efficiency, and consistency of our products. That is why we have invested in new production platforms, like recombinant rabbit monoclonals, alpaca nanobodies, and adopted aggressive QA standards to deliver cutting-edge antibodies with uncompromised quality.
We hope to see you at your next discovery!
We hope to see you at your next discovery!
related products
browse more products
questions and comments
